Handelsbanken Fonder
ITCI

Handelsbanken Fonder’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Handelsbanken Fonder’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,300
Closed -$3.87M – 1582
2025
Q1 		$3.87M Buy
29,300
+2,200
+8% +$274K 0.02% 470
2024
Q4 		$2.26M Buy
27,100
+800
+3% +$65.7K 0.01% 629
2024
Q3 		$1.92M Buy
26,300
+5,000
+23% +$376K 0.01% 678
2024
Q2 		$1.46M Buy
21,300
+2,800
+15% +$194K 0.01% 688
2024
Q1 		$1.28M Hold
18,500
– – 0.01% 746
2023
Q4 		$1.32M Buy
18,500
+1,100
+6% +$63.3K 0.01% 690
2023
Q3 		$906K Buy
17,400
+2,000
+13% +$117K 0.01% 771
2023
Q2 		$975K Buy
15,400
+3,600
+31% +$224K 0.01% 754
2023
Q1 		$639K Hold
11,800
– – ﹤0.01% 895
2022
Q4 		$624K Hold
11,800
– – ﹤0.01% 838
2022
Q3 		$549K Hold
11,800
– – ﹤0.01% 904
2022
Q2 		$674K Hold
11,800
– – ﹤0.01% 841
2022
Q1 		$722K Sell
11,800
-3,600
-23% -$187K ﹤0.01% 956
2021
Q4 		$806K Hold
15,400
– – ﹤0.01% 1016
2021
Q3 		$574K Hold
15,400
– – ﹤0.01% 1270
2021
Q2 		$629K Buy
15,400
+4,000
+35% +$148K ﹤0.01% 1210
2021
Q1 		$387K Hold
11,400
– – ﹤0.01% 1326
2020
Q4 		$363K Hold
11,400
– – ﹤0.01% 1321
2020
Q3 		$293K Hold
11,400
– – ﹤0.01% 1259
2020
Q2 		$293K Buy
+11,400
New +$231K ﹤0.01% 1229

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Handelsbanken Fonder's ITCI Position: Q2 2025 in Review

Handelsbanken Fonder sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 29,300 shares — an estimated $3.87M sold.

Handelsbanken Fonder first reported a position in ITCI in Q2 2020 and held it in 20 quarters. The position peaked at $3.87M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Handelsbanken Fonder reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Handelsbanken Fonder sold 29,300 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.87M.
  • Handelsbanken Fonder first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 20 quarters.
  • Handelsbanken Fonder's Intra-Cellular Therapies Inc. position peaked at $3.87M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Handelsbanken Fonder's 13F filing for Q2 2025, filed 12 Aug 2025.